Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary "manifold folding" technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.
This announcement underscores the growing importance of AI in pharmaceutical R&D. By compressing the timeline from concept to IND filing to under two years—compared to the industry average of several years—Oncotelic demonstrates how vector search and AI can dramatically cut costs and speed up the delivery of new therapies. The platform's ability to index nearly all PubMed abstracts also provides a comprehensive knowledge base for researchers, potentially uncovering novel drug targets and biomarkers.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio.
For more information, visit the company's newsroom at https://ibn.fm/OTLC and view the full press release at https://ibn.fm/Ce72F.